Related Experiment Video
Updated: Nov 2, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Sirolimus in the treatment of kaposiform lymphangiomatosis
Jiangyuan Zhou1, Kaiying Yang1, Siyuan Chen2
1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, #37# Guo-Xue-Xiang, Chengdu, 610041, China.
Background:
Kaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA. Sirolimus, which is an inhibitor of mammalian target of rapamycin, has been shown to have promising potential in the treatment of complicated vascular anomalies. The aim of this study was to introduce the use of sirolimus for the treatment of KLA and to highlight the challenges of managing this refractory disease.
Results:
We reported seven patients with KLA who received sirolimus therapy in our center. Combined with previously reported cases, 58.3% achieved a partial response, 25.0% had stable disease, and 16.7% experienced disease progression. No severe sirolimus-related adverse events occurred during treatment.
Conclusions:
This study suggests that sirolimus is currently an option for the treatment of KLA, and it is hoped that more specific therapies will be developed in the future. Rapid advances in basic science and clinical practice may facilitate the development of important new treatments for KLA.
Insights
Sirolimus shows promise for treating Kaposiform lymphangiomatosis (KLA), a rare lymphatic anomaly. This mTOR inhibitor offers a potential treatment option for this challenging condition with manageable side effects.
Area of Science:
- Vascular Anomalies
- Pediatric Oncology
- Dermatology
Background:
- Kaposiform lymphangiomatosis (KLA) is a rare, aggressive subtype of generalized lymphatic anomaly.
- KLA presents a poor prognosis with no established standard treatment due to limited understanding.
- Complicated vascular anomalies have shown potential therapeutic response to sirolimus, an mTOR inhibitor.
Purpose of the Study:
- To evaluate the efficacy of sirolimus in treating Kaposiform lymphangiomatosis.
- To describe the clinical challenges associated with managing KLA.
- To introduce sirolimus as a potential therapeutic option for KLA.
Main Methods:
- Retrospective case series of seven KLA patients treated with sirolimus.
- Analysis of treatment outcomes including partial response, stable disease, and progression.
- Review of previously reported cases to augment sample size and outcomes.
Main Results:
- Sirolimus therapy demonstrated efficacy in a combined analysis of 58.3% partial response and 25.0% stable disease.
- Only 16.7% of patients experienced disease progression.
- No severe sirolimus-related adverse events were reported, indicating a favorable safety profile.
Conclusions:
- Sirolimus represents a viable treatment option for Kaposiform lymphangiomatosis.
- Further research and development of targeted therapies are needed for KLA.
- Advances in basic science and clinical practice may lead to improved KLA treatments.
More Related Videos
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018